aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference
June 20 2023 - 8:00AM
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics
company engaged in the discovery and development of first-in-class
medicines from its proprietary tRNA synthetase platform, today
announced that the company will present on its lead therapeutic
candidate, efzofitimod, at the World Association for Sarcoidosis
and Other Granulomatous Disorders (WASOG) Conference, which is
scheduled to take place June 19 – 21, 2023, in Stockholm, Sweden.
“Efzofitimod is the most advanced
investigational treatment in clinical development for sarcoidosis.
With a novel myeloid-cell focused mechanism that downregulates
inflammatory responses upstream of other targets, efzofitimod
provides a differentiated approach to resolving inflammation and
preventing the progression of fibrosis compared to existing
treatments and others in development,” said Sanjay S. Shukla, M.D.,
M.S., President and CEO of aTyr. “The Phase 3 EFZO-FIT™ study,
which is currently enrolling patients with pulmonary sarcoidosis in
the U.S., Europe and Japan, is expected to be the largest
interventional study in pulmonary sarcoidosis and represents an
important step forward in developing a potential new treatment for
patients with this debilitating disease.”
Details of the presentations appear below. The
poster will be available on the aTyr website once presented.
Title: Efzofitimod: A New Myeloid-Cell
Focused Mechanism to Downregulate Inflammatory Responses in
Pulmonary SarcoidosisFormat:
PresentationPresenter: Leslie A. Nangle,
Ph.D.Date and Time: Tuesday, June 20, 2023, at
11:55 a.m.
Title: EFZO-FIT™: A Phase 3 Study of
Efzofitimod, a Novel Immunomodulator for the Treatment of Pulmonary
Sarcoidosis Format: Poster
PresentationDate and Time: Tuesday, June 20, 2023,
at 3:14 p.m.
About
Efzofitimod
aTyr is developing efzofitimod as a potential
therapeutic for patients with fibrotic lung disease. Efzofitimod, a
fusion protein comprised of the immunomodulatory domain of
histidyl-tRNA synthetase fused to the FC region of a human
antibody, is a selective modulator of neuropilin-2 that
downregulates innate and adaptive immune response in inflammatory
disease states. aTyr’s lead indication for efzofitimod is pulmonary
sarcoidosis, a major form of interstitial lung disease. Clinical
proof-of-concept for efzofitimod was recently established in a
Phase 1b/2a multiple-ascending dose, placebo-controlled study of
efzofitimod in patients with pulmonary sarcoidosis, which
demonstrated safety and a consistent dose response and trends of
benefit of efzofitimod compared to placebo on key efficacy
endpoints, including steroid reduction, lung function, clinical
symptoms and inflammatory biomarkers. aTyr is currently conducting
EFZO-FIT™, a global pivotal Phase 3 study of efzofitimod in
pulmonary sarcoidosis.
About aTyr
aTyr is a biotherapeutics company engaged in the
discovery and development of first-in-class medicines from its
proprietary tRNA synthetase platform. aTyr’s research and
development efforts are concentrated on a newly discovered area of
biology, the extracellular functionality and signaling pathways of
tRNA synthetases. aTyr has built a global intellectual property
estate directed to a potential pipeline of protein compositions
derived from 20 tRNA synthetase genes and their extracellular
targets. aTyr’s primary focus is efzofitimod, a clinical-stage
product candidate which binds to the neuropilin-2 receptor and is
designed to downregulate immune engagement in fibrotic lung
disease. For more information, please visit www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are usually
identified by the use of words such as “believes,” “expects,”
“intends,” “may,” “plans,” “forward,” “potential,” “will,” and
variations of such words or similar expressions. We intend these
forward-looking statements to be covered by such safe harbor
provisions for forward-looking statements and are making this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements include, among others,
statements regarding the potential of efzofitimod to provide a
differentiated approach to resolving inflammation and preventing
the progression of fibrosis, and the potential applications of
efzofitimod. These forward-looking statements also reflect our
current views about our plans, intentions, expectations, strategies
and prospects, which are based on the information currently
available to us and on assumptions we have made. Although we
believe that our plans, intentions, expectations, strategies and
prospects, as reflected in or suggested by these forward-looking
statements, are reasonable, we can give no assurance that the
plans, intentions, expectations or strategies will be attained or
achieved. All forward-looking statements are based on estimates and
assumptions by our management that, although we believe to be
reasonable, are inherently uncertain. Furthermore, actual results
may differ materially from those described in these forward-looking
statements and will be affected by a variety of risks and factors
that are beyond our control including, without limitation,
uncertainty regarding geopolitical and macroeconomic events, risks
associated with the discovery, development and regulation of our
product candidates, the risk that we or our partners may cease or
delay preclinical or clinical development activities for any of our
existing or future product candidates for a variety of reasons
(including difficulties or delays in patient enrollment in planned
clinical trials), the possibility that existing collaborations
could be terminated early, and the risk that we may not be able to
raise the additional funding required for our business and product
development plans, as well as those risks set forth in our most
recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q
and in our subsequent SEC filings. Except as required by law, we
assume no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact:Ashlee DunstonDirector,
Investor Relations and Corporate
Communicationsadunston@atyrpharma.com
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2024 to May 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From May 2023 to May 2024